PAMIDRONATE MONOSODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C3H10NO7P2.Na
Molecular Weight	257.0513
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].NCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

InChIKey=AFICAMMULQSNNG-UHFFFAOYSA-M

InChI=1S/C3H11NO7P2.Na/c4-2-1-3(5,12(6,7)8)13(9,10)11;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10342945

Pamidronic acid (Pamidronate Disodium) is a bone resorption inhibitor. The principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment of hypercalcemia, pamidronate disodium inhibits bone resorption apparently without inhibiting bone formation and mineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that pamidronate disodium inhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by various tumors in animal studies. Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18327899 \| https://www.ncbi.nlm.nih.gov/pubmed/10620343 \| https://www.ncbi.nlm.nih.gov/pubmed/11160603	Inhibitor 8297		55.9 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Malignant hypercalcemia 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8429	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991
Paget's disease 16 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8429	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991
Osteolytic bone metastases of breast cancer 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8429	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991

C_max

Value	Dose	Analyte	Population
1.92 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9115053/	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.44 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	60 mg single, intravenous dose: 60 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.61 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.73 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
10.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9115053/	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	60 mg single, intravenous dose: 60 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
5.6 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 5.6 mg/kg, 3 times / day Route: oral Route: multiple Dose: 5.6 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	unhealthy, adult n = 9 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 9 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf
120 mg/kg 1 times / day multiple, intravenous Overdose Dose: 120 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Fever, Hypotension... AEs leading to discontinuation/dose reduction: Fever Hypotension Taste perversion Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Interstitial pneumonitis, Hypocalcemia... AEs leading to discontinuation/dose reduction: Interstitial pneumonitis Hypocalcemia Bone pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf

AEs

AE	Significance	Dose	Population
Diarrhea	Disc. AE	5.6 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 5.6 mg/kg, 3 times / day Route: oral Route: multiple Dose: 5.6 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	unhealthy, adult n = 9 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 9 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf
Hypocalcemia	Disc. AE	120 mg/kg 1 times / day multiple, intravenous Overdose Dose: 120 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Fever	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Hypotension	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Taste perversion	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Bone pain	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Hypocalcemia	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Interstitial pneumonitis	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCTN2 66 OCTN1 29	CYP 270 UGT 192

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OCTN1 29	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/B978178242076750006X	yes
OCTN2 71	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/B978178242076750006X	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20927lbl.pdf#page=1 Page: 1.0	no
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20927lbl.pdf#page=1 Page: 1.0	no

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY553353	https://www.001chemical.com/chem/40391-99-9
3B Scientific (Wuhan) Corp	3B2-1670	http://www.3bsc.com/index/pro_info.php?id=55389
AA Blocks	AA00732G	https://www.aablocks.com/goods/Goods/detail?id=AA00732G
AEchem Scientific Corp., USA	AE032040	http://www.aechemsc.com/info_products/AE032040.php
AK Scientific, Inc. (AKSCI)	2631AH	http://www.aksci.com/item_detail.php?cat=2631AH
Aaron Chemicals	AR0073U8	http://www.aaronchem.com/40391-99-9
Acadechem	ACDS-033198	http://www.acadechemical.com/product/107897
Achemtek	0104-020132	http://www.achemtek.com/40391-99-9
Adooq BioScience	A11685	https://www.adooq.com/pamidronic-acid.html
Angel Pharmatech	AG111246	http://www.angelpharmatech.com/40391-99-9.html
ApexBio Technology	B1807	http://www.apexbt.com/pamidronate.html
Ark Pharm	AK113121	http://www.arkpharminc.com/products/40391-99-9.html
Aurora Fine Chemicals LLC	A13.111.373	http://online.aurorafinechemicals.com/info?ID=A13.111.373
AvaChem Scientific	2606A	http://www.avachem.com/productSearch.asp?2606A
BLD Pharm	BD01332989	http://www.bldpharm.com/products/1159812-33-5.html
BLD Pharm	BD146697	http://www.bldpharm.com/products/40391-99-9.html
BioChemPartner	BCP17709	http://www.biochempartner.com/40391-99-9-BCP17709
BioCrick	BCC4693	http://www.biocrick.com/Pamidronate-BCC4693.html
CSNpharm	CSN11650	https://www.csnpharm.com/products/pamidronic-acid.html
Chem Scene	CS-7787	http://www.chemscene.com/40391-99-9.html
ChemMol	99097528	http://www.chemmol.com/chemmol/99097528.html
Chemspace	CSSB00000052565	https://chem-space.com/CSSB00000052565
Clearsynth	CS-O-30893	http://www.clearsynth.com/en/CSO30893.html
Clearsynth	CS-O-02157	https://www.clearsynth.com/en/CSO02157.html
DC Chemicals	DCAPI1175	http://www.dcchemicals.com//product_show-Pamidronic_acid.html
Debye Scientific	DB-049579	http://www.debyesci.com/cas_40391-99-9.html
Finetech	FT-0630610	http://www.finetechnology-ind.com/prod/detail/pub/40391-99-9.html
Hairui	HR124492	http://www.hairuichem.com/en/product/40391-99-9.html
MedChem Express	HY-B0012	https://www.medchemexpress.com/Pamidronic_acid.html
Molcore	MC553353	https://www.molcore.com/product/40391-99-9
MuseChem	R003777	https://www.musechem.com/product/R003777.html
OChem	7839	http://www.ocheminc.com/index.php?act=psearch&pid=391P999
Selleck Chemicals	S2063	http://www.selleckchem.com/products/pamidronic-acid.html
Sinfoo Biotech	S017541	http://www.sinfoobiotech.com/product/1020939
Smolecule	S591193	https://www.smolecule.com/products/s591193
THE BioTek	bt-308550	https://www.thebiotek.com/product/others/bt-308550
Vesino Industrial Co Ltd	VA11481	http://www.vsnchem.com/goto/product/22804/
abcr GmbH	AB492176	http://www.abcr.com/shop/en/AB492176
eNovation Chemicals	D280137	https://www.enovationchem.com/ProductDetails.asp?ProductID=D280137
eNovation Chemicals	Y1047107	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1047107
iChemical	EBD36833	http://www.ichemical.com/products/40391-99-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-4373491291	https://mcule.com/MCULE-4373491291/

PubMed

Title	Date	PubMed
[A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].	2000 Aug	10969600
Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.	2001	11596836
[Paget disease or fibrous dysplasia of the radius?--A case report].	2001	11582993
Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.	2001	11303710
Analgesic effect of bisphosphonates in mice.	2001 Apr	11275384
Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.	2001 Apr	11254825
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.	2001 Apr 1	11283917
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.	2001 Apr 6	11286476
Analysis of skeletal-related events in breast cancer and response to therapy.	2001 Aug	11544572
Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.	2001 Dec	11721169
Treatment of osteoporosis with bisphosphonates.	2001 Feb	11285996
Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate.	2001 Jan-Feb	11247319
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.	2001 Jul 15	11454892
[Analgesic effect of Pamidronate on bone pain in patient with hypertrophic pulmonary osteoarthropathy].	2001 Jun	11416808
Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination.	2001 Jun 4	11376962
Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK.	2001 Mar	11301665
Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial.	2001 Mar	11277274
Bisphosphonate treatment inhibits the growth of prostate cancer cells.	2001 Mar 15	11289137
[Two cases of effective weekly paclitaxel administration for metastatic breast cancer].	2001 Nov	11729485
Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.	2001 Nov	11719835
Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.	2001 Nov 1	11673519
Paget's disease of the spine and its management.	2001 Oct	11718191
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.	2001 Oct	11595616
Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.	2001 Oct	11593054
The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease.	2001 Oct	11567178
Prevention of bone loss and fracture after lung transplantation: a pilot study.	2001 Oct 15	11602851
Hypercalcemia in patients with oral squamous cell carcinoma.	2001 Sep	11642565
Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits.	2001 Sep	11603525
Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison.	2001 Sep	11589787
Bisphosphonates for osteoporosis.	2001 Sep	11586803
Trastuzumab and breast cancer.	2001 Sep 27	11575298
Bone loss accompanying medical therapies.	2001 Sep 27	11575293
Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.	2001 Sep 7	11435429

Patents

Sample Use Guides

In Vivo Use Guide

Moderate Hypercalcemia The recommended dose of pamidronate disodium in moderate hypercalcemia (corrected serum calcium* of approximately 12 to 13.5 mg/dL) is 60 to 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (i.e., >2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency. Severe Hypercalcemia The recommended dose of pamidronate disodium in severe hypercalcemia (corrected serum calcium* >13.5 mg/dL) is 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (i.e., >2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency.

Route of Administration: Intravenous

In Vitro Use Guide

BMSCs proliferation was significantly inhibited with 10(−4) M Pamidronic acid (pamidronate) after 72h and 168h, and with 6 × 10(−5) M pamidronate after 168h. Alveolar osteoblasts cultured in osteogenic medium exhibited significantly lower alkaline phosphatase (AP) activities with 6 × 10(−5) M and 10(−4) M pamidronate (39% and 16% of the unsupplemented group) as compared to all lower concentration groups after 168h.

Name

Type

Language

PAMIDRONATE MONOSODIUM

Common Name

English

J710.127I

Code

English

PHOSPHONIC ACID, (3-AMINO-1-HYDROXYPROPYLIDENE)BIS-, MONOSODIUM SALT

Systematic Name

English

3-AMINO-1-HYDROXY-1,1-PROPANEDIPHOSPHONIC ACID MONOSODIUM SALT

Systematic Name

English

PAMIDRONIC ACID MONOSODIUM SALT

Common Name

English

Code System Code Type Description

EVMPD

SUB26399

Created by admin on Sat Dec 16 08:46:13 GMT 2023 , Edited by admin on Sat Dec 16 08:46:13 GMT 2023

PRIMARY

PUBCHEM

14157377

Created by admin on Sat Dec 16 08:46:13 GMT 2023 , Edited by admin on Sat Dec 16 08:46:13 GMT 2023

PRIMARY

FDA UNII

MUA93Q6K1J

Created by admin on Sat Dec 16 08:46:13 GMT 2023 , Edited by admin on Sat Dec 16 08:46:13 GMT 2023

PRIMARY

CAS

89131-02-2

Created by admin on Sat Dec 16 08:46:13 GMT 2023 , Edited by admin on Sat Dec 16 08:46:13 GMT 2023

PRIMARY

ACTIVE MOIETY


					OYY3447OMC

PAMIDRONIC ACID

SUBSTANCE RECORD


					MUA93Q6K1J

PAMIDRONATE MONOSODIUM

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10342945

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10342945

C_max

T_1/2

Drug as perpetrator